Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eudract

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: eudract. Displaying page 9 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    EudraCT Number: 2013-004668-71 Sponsor Protocol Number: 11/0499 Start Date*: 2014-09-25
    Sponsor Name:University College London
    Full Title: An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa
    Medical condition: Childhood systemic polyarteritis nodosa (PAN)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004866 10036026 Polyarteritis nodosa of childhood LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) PT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000777-24 Sponsor Protocol Number: TAK-994-1501 Start Date*: 2021-05-17
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy W...
    Medical condition: Narcolepsy With or Without Cataplexy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FR (Prematurely Ended) CZ (Completed) NL (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005163-10 Sponsor Protocol Number: DS5565-A-E311 Start Date*: 2014-12-18
    Sponsor Name:Daiichi Sankyo Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia
    Medical condition: DS-5565 is being developed for the treatment of pain associated with fibromyalgia (FM).
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10048439 Fibromyalgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) EE (Completed) LT (Completed) HU (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-024614-66 Sponsor Protocol Number: C38072/3082 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed) HU (Completed) PL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2010-024006-35 Sponsor Protocol Number: C38072/3083 Start Date*: 2011-05-05
    Sponsor Name:Teva Branded Pharmaceutical Products, R&D, Inc.
    Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000650-11 Sponsor Protocol Number: HEP002 Start Date*: 2014-09-15
    Sponsor Name:Promethera Biosciences
    Full Title: A prospective, open label, multicountry, efficacy and safety study of several infusions of HepaStem in Urea Cycle Disorders pediatric patients.
    Medical condition: The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are seven disorders to be investigated: carbamoylphosphate synthetase I deficiency [CP...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012782-63 Sponsor Protocol Number: P06086 Start Date*: 2010-01-08
    Sponsor Name:Schering-Plough Research Institution, A Division of Schering Corporation
    Full Title: Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anemia
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    9.1 10019744 PT
    9.1 10021881 SOC
    9.1 10019805 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000161-75 Sponsor Protocol Number: UCL/14/0795 Start Date*: 2017-12-18
    Sponsor Name:University College London
    Full Title: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer...
    Medical condition: High grade serous or endometrioid ovarian, fallopian and peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003866-34 Sponsor Protocol Number: 2553 Start Date*: 2012-09-24
    Sponsor Name:North Bristol NHS Trust (NBT)
    Full Title: A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administ...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10034008 Parkinson's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003904-21 Sponsor Protocol Number: ABT-001 Start Date*: 2016-08-01
    Sponsor Name:Abeona Therapeutics Inc
    Full Title: Phase I/II gene transfer clinical trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
    Medical condition: MPS IIIA is a devastating lysosomal storage disease, caused by a N-sulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progres...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004090-29 Sponsor Protocol Number: AVD100521 Start Date*: 2005-02-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd [...]
    1. GlaxoSmithKline Research & Development Ltd
    2. GlaxoSmithKline R&D
    Full Title: A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type ...
    Medical condition: atherosclerosis in Type 2 Diabetes Mellitus patients with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) LV (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-002282-19 Sponsor Protocol Number: MENAC-2017-03 Start Date*: 2016-05-17
    Sponsor Name:Norwegian University of Science and technology
    Full Title: A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in a...
    Medical condition: cachexia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004665-33 Sponsor Protocol Number: VX06-950-106 Start Date*: 2007-04-04
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral R...
    Medical condition: Hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005129-57 Sponsor Protocol Number: KCT02/2012-VICTORY Start Date*: 2013-02-21
    Sponsor Name:Krka, d.d., Novo mesto
    Full Title: The Efficacy and Safety of Valsartan and Combination of Valsartan and Hydrochlorothiazide in the Treatment of Patients with mild to moderate Arterial Hypertension.
    Medical condition: Patients with mild to moderate arterial hypertension.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020775 Hypertension arterial LLT
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-000570-25 Sponsor Protocol Number: CSL312_3001 Start Date*: 2021-02-09
    Sponsor Name:CSL Behring LLC
    Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic tr...
    Medical condition: Hereditary angioedema
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) NL (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-004686-41 Sponsor Protocol Number: IBA1160 Start Date*: 2020-12-02
    Sponsor Name:Helsinn Healthcare SA
    Full Title: MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
    Medical condition: Patients treated with IV moderately emetogenic chemotherapy and at high risk of chemotherapy induced nausea and vomiting (CINV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) CZ (Completed) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004760-39 Sponsor Protocol Number: P05685 Start Date*: 2009-04-03
    Sponsor Name:Schering Plough Research Institute, A Division of Schering Corporation
    Full Title: A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterfer...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 Hepatitis C PT
    9.1 10021881 Infections and infestations SOC
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020744-35 Sponsor Protocol Number: D4300C00002 Start Date*: 2010-10-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Re...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) LV (Completed) LT (Completed) CZ (Completed) PT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020745-27 Sponsor Protocol Number: D4300C00003 Start Date*: 2010-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Respon...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Completed) ES (Completed) FR (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-020743-12 Sponsor Protocol Number: D4300C00001 Start Date*: 2010-10-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Res...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) SK (Completed) HU (Completed) EE (Completed) PL (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 12:59:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA